Tesaro Inc. has acquired rights to nausea drug rolapitant and one other drug from OPKO Health Inc. for $121 million Including milestones, double-digit, tiered royalties and a 10 percent equity position in Tesaro. Rolapitant was a Schering-Plough Corp. property, but OPKO nabbed it for just $2 million up front following Schering's 2009 merger with Merck and Co. Inc.